A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date6/01/25 → 5/01/30

Clinical Trial Phase

  • Phase III (a & b)